Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

COCH vs BVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: COCH 1 – 5 BVS Matrix Metrics: COCH 2 – 8 BVS

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin).

  • Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCH vs BVS
COCH NASDAQ
Envoy Medical, Inc. Class A Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$6.70
+0.0% 1D
Market Cap $51.9M
TTM Revenue $231,000
Forward P/E N/M
Beta / 30D Vol 4.94β · 3352% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (348.7% over 20 days), RSI 78
RSI-14: 77.7 · SMA20: $6.79 · SMA50: $3.12
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81

6-Pillar Scorecard Institutional Category Breakdown (COCH 1 – 5 BVS)

Columns: Metric · COCH · BVS
1. Valuation Multiples BVS
Forward P/E N/M 11.1x
Trailing P/E N/M 12.3x
PEG Ratio N/M 1.20x
EV / Revenue 119.2x 1.5x
2. Growth & Scale BVS
Revenue Growth (YoY) +57.1% +2.7%
Earnings Growth (YoY) +0.0% +69.7%
TTM Revenue (USD) $231,000 $586M
Market Cap $51.9M $681.3M
3. Profitability & Quality BVS
Gross Margin N/A 68.7%
Operating Margin -10261.0% 10.1%
Net Profit Margin 0.0% 9.8%
Return on Equity (ROE) 0.0% 25.8%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) -$21M $85M
Cash Flow Margin N/A 14.5%
Net Cash / Leverage $24M Net Cash $199M Net Debt (0.96x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning COCH
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 448.1% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity N/A 58.6% of Rev ($343M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCH (2) vs BVS (8)
Institutional Metric COCH BVS Criterion Row Edge
Market Capitalization
Scale
$51.9M $681.3M Larger Scale BVS
Trailing P/E Ratio
Valuation
N/M 12.3x Lower Multiple BVS
Forward P/E Ratio
Valuation
N/M 11.1x Lower Multiple BVS
Revenue Growth (YoY)
Growth
+57.1% +2.7% Higher Growth COCH
Operating Margin (TTM)
Profitability
-10261.0% 10.1% Higher Margin BVS
Net Profit Margin
Profitability
0.0% 9.8% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
0.0% 25.8% Higher ROE BVS
52-Week Range Position
Momentum
89% ($0–$7) 36% ($6–$16) Stronger Trend COCH
Beta / 30D Volatility
Risk Regime
4.94β · 3352% Vol 0.85β · 74% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
35.1 / 100 (SELL) 46.2 / 100 (HOLD) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$231,000 $586M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 68.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 119.2x EV/Rev 1.20x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($24M Net Cash) $85M ($199M Net Debt (0.96x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCH +1058.66 pp
COCH: +1024.35% · BVS: -34.31%
3M Horizon COCH +827.41 pp
COCH: +797.88% · BVS: -29.53%
6M Horizon COCH +838.52 pp
COCH: +844.99% · BVS: +6.47%
1Y Horizon COCH +796.38 pp
COCH: +843.4% · BVS: +47.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCH Revenue BVS Revenue COCH Op. Margin BVS Op. Margin Margin Leader
FY2019 N/A $340M N/A 9.2% BVS
FY2020 N/A $320M N/A 6.6% BVS
FY2021 N/A $430M N/A 2.8% BVS
FY2022 $0M $510M -3673.4% -32.7% BVS
FY2023 $0M $510M -5809.8% -16.0% BVS
FY2024 $0M $570M -8558.2% -2.7% BVS
FY2025 $0M $570M -9240.7% 9.5% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $51.9M market capitalization and -10261.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published

Investor FAQ COCH vs BVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over Envoy Medical, Inc. (COCH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). COCH carries a Unified Composite Score of 35.1/100 (SELL) at $6.70 (N/M Forward P/E, -10261.0% operating margin), whereas BVS carries 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin). Growth vs. Quality Trade-Off: BVS earns the overall head-to-head edge with a stronger Unified Composite Score (46.2/100 HOLD vs. COCH 35.1/100 SELL) and 0.85β · 74% Vol risk profile, whereas COCH leads top-line expansion (+57.1% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: COCH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 77.7); meanwhile BVS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: COCH posts +57.1% YoY revenue growth and +0.0% YoY earnings growth on $231,000 TTM revenue (N/A gross margin, -10261.0% operating margin), compared with BVS at +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), COCH cumulative revenue shifted N/A while BVS shifted +67.6%. In operating R&D and SG&A reinvestment, COCH deploys N/A (0 90-day corporate R&D disclosures) versus 58.6% of Rev ($343M) (0 disclosures) for BVS.

BVS screens cheaper on headline valuation multiples. COCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 119.2x EV/Revenue (unreported FCF margin), whereas BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCH (0.0% ROE) versus BVS (25.8% ROE) capital efficiency.

In options market volatility and institutional positioning, COCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.94β · 3352% Vol realized risk). By comparison, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.